Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuvilex could get up to $50mm in at-the-market financing

Executive Summary

Nuvilex Inc. (cell and gene therapy) could raise up to $50mm in an at-the-market private placement of common shares. Chardan Capital Markets is the placement agent. Upon the company’s approval, Chardan will offer up to a maximum number of shares (determined by Nuvilex).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement
    • Other
    • Private Investment in Public Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register